PCI Biotech: CEO resigns to assume new position
Oslo (Norway), 28 March 2022 – PCI Biotech (OSE: PCIB) announces today that CEO, Dr Per Walday has resigned to assume a new position. Dr Walday has a notice period of six months, and he will step down from his position by the end of September 2022, or earlier. The Board of Directors will initiate a succession process.
“On behalf of the entire company, I wish Dr Walday all the best in his new endeavours and sincerely thank him for his 14 years period as CEO of PCI Biotech. Per will surely be missed by us all”, says Hans Peter Bøhn, Chairperson of the Board of Directors.
“I look forward to assuming a new position but will thoroughly miss all my fantastic colleagues at PCI Biotech. It has been a long and exciting journey for me, but it is time to let someone else take the helm of PCI Biotech. The company has a very strong and competent team and an exciting technology platform with strong data supporting applications within important emerging therapeutic modalities. I am confident that the team will succeed in delivering value to both patients and shareholders, and I will follow the company’s path and progress closely”, says Per Walday, CEO.
For further information, please contact:
Hans Peter Bøhn, Chairperson of the Board of Directors
Mobile: +47 9171 1597
About PCI Biotech
PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.
The company’s lead programme fimaVacc aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through an extensive Phase I study in healthy volunteers and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Kommuniké från årsstämma i Corline Biomedical AB (publ)18.5.2022 19:08:12 CEST | Pressemelding
Idag den 18 maj 2022 hölls årsstämma i Corline Biomedical AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades enhälligt. Fastställande av resultat Bolagsstämman fastställde resultat- och balansräkningarna och beslutade, i enlighet med styrelsens förslag, att resultatet enligt den fastställda resultaträkningen skulle överföras i ny räkning. Någon utdelning lämnas inte. Ansvarsfrihet Bolagsstämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för förvaltningen av Bolagets angelägenheter under räkenskapsåret 2021. Fastställande av antalet styrelseledamöter, styrelsesuppleanter och antalet revisorer Stämman beslutade att styrelsen ska bestå av sex (6) styrelseledamöter samt en (1) styrelsesuppleant. Vidare beslutades att bolaget ska fortsätta ha ett registrerat revisionsbolag som revisor. Fastställande av arvoden till styrelsen och revisorn Bolagsstämman beslutade att styrelsearvode skulle utgå med två prisbasbelopp varde
Notice of Annual General Meeting of EPH EUROPEAN PROPERTY HOLDINGS PLC (the “Company”)18.5.2022 19:00:00 CEST | Press release
NOTICE is hereby given that the Annual General Meeting of the Company will be held on 9th June 2022 at 11 AM at Hotel Amathus, 75 Amathus Avenue, 4532 Limassol, Cyprus, for the following purposes: 1) Approval of the results for the year ended 31 December 2021 To approve the annual report proposed by the Board of Directors of the Company and the consolidated financial statements of the Company as at 31 December 2021. The annual business report and the auditor’s report are available for examination by shareholders (i) at the Company’s registered office located at 12 Menandrou, ELIONA TOWER, Flat/ Office 207, 1066 Nicosia, Cyprus, (ii) at the office of Valartis Advisory Services SA, St. Annagasse 18, 8001 Zurich, Switzerland and (iii) on the Company’s website: https://europeanpropertyholdings.com/. 2) To consider the recommendation of the Board of Directors of the Company to not declare a dividend. 3) Election of Board of Directors Pursuant to the provisions of the Company’s Articles of A
Vallourec first quarter 2022 results - New initiatives launched to be cycle-proof18.5.2022 18:15:00 CEST | Press release
Meudon (France), May 18, 2022 Vallourec first quarter 2022 results New initiativeslaunched to be cycle-proof Q1 2022 results in line with expectations €916 million revenue, a 30% year-over-year increase led by North America€45 million reported EBITDA negatively impacted by the iron ore mine shutdown; normalized level of ~€130 million1€(230) million Free Cash Flow impacted by €(217) million working capital build-up reflecting higher forward volume expectations and raw material price increases FY 2022 EBITDA now expected to be significantly above 2021, despite Q1 impacted by mine shutdown €230million of recurring EBITDA and €250million ongoing cash up-lift (+€100million compared to November 2021 announcement) Launching the closure process of German sites and refocusing European plantsStreamline corporate structure to better manage a reshaped industrial footprint and a leaner organization Philippe Guillemot, Chairman of the Board of Directors and Chief Executive Officer, declared: “Steppi
Changes in financial results publication18.5.2022 18:01:16 CEST | Press release
PRFoods AS declares that 2021/2022 financial year 9 months unaudited results will be published, according to Stock Exchange rules no later than two months after end of the reporting period, 31.5.2022. Although interim report will be unaudited, PRFoods has required a third party assessment of the impact of sale of Heimon Kala Oy, taking into account that final purchase price is dependent on certain conditions subsequent presumed to be met before publication. Indrek Kasela AS PRFoods Member of the Management Board Phone: +372 452 1470 email@example.com www.prfoods.ee
PRESS RELEASE: NACON: WRC GENERATIONS: THE MOST COMPLETE RALLY GAME IS COMING IN OCTOBER!18.5.2022 17:46:00 CEST | Press release
WRC GENERATIONS: THE MOST COMPLETE RALLY GAME IS COMING IN OCTOBER! Lesquin, 18th May 2022 - NACON and the studio KT Racing are pleased to announce their new rally game, WRC Generations, the official video game of the FIA World Rally Championship, scheduled for release in Autumn 2022 on PlayStation®4, PlayStation®5, Xbox One, Xbox Series X|S, Nintendo Switch and Steam for PC. The result of 7 years of collaboration with legendary drivers, who have already made WRC 10 and WRC 9 the references of the genre, the latest entry in the series is an authentic and comprehensive rally racing simulation, giving players the chance to drive powerful cars in the most famous rallies of all time! Check out the announcement trailer for WRC Generations: [link] An unrivalled level of realism Never before have games come this close to the real-life World Rally Championship! Hailed by both critics and professionals, this year's WRC simulation has been reinforced with numerous improvements and optimisations